

Supplementary Table 1. Baseline characteristics of patients receiving fludarabine/cyclophosphamide/rituximab, obinutuzumab/chlorambucil, and chlorambucil monotherapy.

	FCR	GC	Cbl
Age (median, range)	62 (34–86)	71 (53–84)	57 (40–80)
Sex			
Male	75 (64.1)	13 (43.3)	11 (45.8)
Female	42 (35.9)	17 (56.7)	13 (54.2)
ECOG-PS			
0–1	113 (96.6)	26 (86.7)	22 (91.7)
2–4	4 (3.4)	4 (13.3)	2 (8.3)
Largest tumor diameter			
≤ 5 cm	110 (94.0)	29 (96.7)	23 (95.8)
> 5 cm	7 (6.0)	1 (3.3)	1 (4.2)
Rai stage			
0	1 (0.9)	0 (0.0)	0 (0.0)
I	25 (21.4)	4 (13.3)	14 (58.3)
II	30 (25.6)	4 (13.3)	5 (20.8)
III	27 (23.1)	14 (46.7)	3 (12.5)
IV	34 (29.1)	8 (26.7)	2 (8.3)
Binet stage			
A	10 (8.5)	4 (13.3)	7 (29.2)
B	47 (40.2)	7 (23.3)	12 (50.0)
C	60 (51.3)	19 (63.3)	5 (20.8)

Data are presented as medians (ranges) or numbers (percentages).

Abbreviations: Cbl, chlorambucil; ECOG-PS, Eastern Cooperative Oncology Group performance status; FCR, fludarabine/cyclophosphamide/rituximab; GC, obinutuzumab/chlorambucil.